Sanofi postdoctoral research program is designed to provide an opportunity to a high-caliber Ph.D. graduate to be part of an industry leading scientific team working on understanding and solving the world’s most difficult biomedical problems facing patients.
Over the course of the 2–3-year program, the scientist will push the boundaries of innovation by conducting groundbreaking research. The program provides a unique work experience where the successful scientist will be addressing a research problem with an academic focus and drug discovery perspective. Postdoctoral scientist will learn what it means to work in Sanofi’s cutting-edge environment, as he/she prepares for a career in global healthcare discovery industry.
We are seeking a highly motivated postdoctoral research scientist to understand the novel Immune Checkpoint Biology in immune regulation. The scientist will work on a program to dissect the complex crosstalk between immune inhibitory checkpoint receptors and activating receptors. and their implication in immune modulation. The successful candidate will have expertise in Immunology, hands on experience in cellular biochemistry, and broad knowledge of checkpoint receptors biology.
Key Responsibilities
Responsible for formulating research hypothesis and apply scientific expertise to design and execute appropriate experiments to validate the hypothesis.
Collaborate with Immunology and Inflammation Bioinformatics Team to identify immune checkpoint receptor gene polymorphism and establish correlation to disease.
Works closely with proteomic team to understand the protein interaction and checkpoint receptor signal pathways.
Works independently on assignments using knowledge and work experience. Gathers input from colleagues and management to address issues.
Prepare and publish manuscripts, present research work in internal and external meetings.
Basic Qualifications
PhD in Biological science/ Immunology, Cell biology, Microbiology or related field.
Expertise in various in vitro immunological assays and signal transduction assay is required.
Strong background knowledge in innate and adaptive immunology is required.
Strong skills in flow cytometry, stable cell line generation, molecular biology, cell culture and experience with biochemical techniques- western blotting, immunoprecipitation are essential.
Relevant experience or broad knowledge in checkpoint immune receptor biology in autoimmunity is a plus.
Proven ability to lead and manage complex research projects, evidence of scholarly publishing, a strong desire to work in a collaborative team environment are required.
Excellent interpersonal and communication skills: impactful oral and written communication.
Creative thinking, ability to work independently, willingness to learn new skills, and the ability to handle multiple tasks are expected.
Sanofi Inc. and its U.S. affiliates are Equal Opportunity and Affirmative Action employers committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status; domestic violence victim status; atypical cellular or blood trait; genetic information (including the refusal to submit to genetic testing) or any other characteristic protected by law.
#GD-SA
#LI-SA
Cambridge, MA
As the specialty care global business unit of Sanofi, we are focused on rare diseases, rare blood disorders, multiple sclerosis, oncology and immunology. More than 30 years since we began, we remain just as committed to and passionate about advancing therapies that offer hope to patients and families.
Our approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, we rapidly grew to become one of the world’s leading biotechnology companies, recognized for our pioneering development of treatments for rare genetic disorders and our innovative contributions to medical science and biomanufacturing.
Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofi’s programs in oncology and immunology. In 2018, with the acquisitions of Bioverativ and Ablynx, we further expanded our focus to include rare blood disorders, bringing deep expertise in hematology.
Our ambition is to be the industry leader in specialty care. We currently provide more than 25 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi laboratories.
Driven by our commitment to patients, we strive to develop strong relationships with our patient communities, listening to their perspectives so that we can truly understand their needs. These collaborations continue to guide and motivate us as we work to push the boundaries of medicine and technology to develop new and better therapies where none existed before.